Status:
RECRUITING
Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis
Lead Sponsor:
Nicholas Breitborde
Conditions:
Psychosis
Schizophrenia
Eligibility:
All Genders
15-35 years
Phase:
NA
Brief Summary
Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with first-episode psychosis: Effects on symptomatology and cognition.
Detailed Description
Functional deficits in prefrontal, limbic, and temporal regions of the brain are well-documented among individuals with psychotic disorders. Mitochondrial dysfunction may contribute to such pathology,...
Eligibility Criteria
Inclusion
- Diagnosis of a schizophrenia-spectrum disorder or mood disorder with psychotic features as determined using the Structured Clinical Interview for the DSM-5.
- Less than 5 years since the onset of frank psychotic symptoms as determined using the Symptom Onset in Schizophrenia Inventory .
- No evidence of a pre-existing intellectual disability defined as a premorbid IQ \>70 as estimated using the Reading subtest of the Wide Range Achievement Test-4.
- Ages 15-35
- Non-smoker for past six months
- Absence of suicidal ideation or behavior over the past month as assessed by the Columbia Suicide Severity Rating Scale
- The American Association for Respiratory Care notes that "no absolute contraindications to oxygen therapy exist when indications \[for oxygen therapy\] are present."
Exclusion
Key Trial Info
Start Date :
December 4 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 7 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04368039
Start Date
December 4 2019
End Date
December 7 2025
Last Update
October 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Harding Hospital
Columbus, Ohio, United States, 43210